United States

Personal Genome Diagnostics hires chief commercial officer

Thursday, March 7, 2013 01:41 PM

Baltimore-based Personal Genome Diagnostics (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, has recruited veteran industry executive Antony Newton as it prepares for accelerated growth.

More... »

Delta Point hires former AstraZeneca exec Michael Hickey

Thursday, March 7, 2013 01:40 PM

Michael Hickey, former vice president of U.S. sales at AstraZeneca and former president of AstraZeneca, Netherlands, has joined Delta Point of Malvern, Pa., as senior vice president of global leadership development.

More... »

Merck names Roger Perlmutter president of Merck Research Laboratories

Thursday, March 7, 2013 01:37 PM

Merck has appointed Roger M. Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003. To ensure a seamless transition, Dr. Perlmutter and Dr. Kim will work closely together for an initial period, after which Dr. Kim will remain with the company as an advisor until his retirement in August.

More... »

Accelovance acquires CRO Radiant Development

Thursday, March 7, 2013 01:32 PM

Rockville, Md.-based CRO  Accelovance has announced the acquisition of Radiant Development, the CRO division of Radiant Research. Terms of the transaction were not disclosed. 

More... »

Marken appoints two independent directors to board

Tuesday, March 5, 2013 04:10 PM

Marken, based in Research Triangle Park, N.C., has appointed two independent directors to its board, as a result of Marken's recent restructuring completed Dec. 21, 2012.  They are Timothy C. Tyson and Michael O'Donnell.

More... »

Trovagene appoints Erlander chief scientific officer

Monday, March 4, 2013 02:15 PM

San Diego-based Trovagene, a developer of transrenal molecular diagnostics, has named Mark Erlander, Ph.D., chief scientific officer.  Erlander has more than 18 years of experience directing research teams with a strong focus in oncology-based molecular diagnostics. 

More... »

GNS Healthcare joins Orion Bionetworks to develop predictive models

Monday, March 4, 2013 02:08 PM

GNS Healthcare has joined in the formation of Orion Bionetworks. This unique alliance will work to transform understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS).

More... »

Accelovance names Boccia oncology medical director

Friday, March 1, 2013 02:45 PM

Accelovance has named Dr. Ralph Boccia, M.D., FACP, oncology medical director.  The Rockville, Md.-based CRO caters to biotech and small/mid-sized pharma sponsors.

More... »

Parent Project Muscular Dystrophy funds UCLA project

Friday, March 1, 2013 12:46 PM

Parent Project Muscular Dystrophy (PPMD) will provide $100,000 to Dr. Stanley Nelson of the University of California, Los Angeles, to examine the genomes of 40 boys with Duchenne muscular dystrophy who are either very mildly affected or very severely affected.  The goal is to identify changes in genes other than dystrophin that may affect the course of the disease.

More... »

Optimer board chairman McKinnell named CEO

Thursday, February 28, 2013 03:09 PM

The board of directors of Jersey City, N.J.-based Optimer Pharmaceuticals has appointed its chairman, Dr. Henry McKinnell, chief executive officer. McKinnell was Pfizer's CEO and chairman from 2001 to 2006 and was with Pfizer from 1971 until his retirement in 2007.

More... »